Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation

被引：6
作者：
Hsiao, Kuang-Chih [1 ,2 ,3 ]
Smart, Joanne [1 ,3 ]
机构：
[1] Epworth HealthCare Richmond, Richmond, Vic, Australia
[2] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[3] Royal Childrens Hosp, Melbourne, Vic, Australia
来源：
PEDIATRIC ALLERGY AND IMMUNOLOGY | 2014年 / 25卷 / 07期
关键词：
SAFETY; EFFICACY; TABLET; RHINOCONJUNCTIVITIS; TOLERABILITY; INITIATION; ALLERGENS;
D O I：
10.1111/pai.12268
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：714 / 715
页数：2
相关论文
共 10 条
  • [1] ASCIA. Australasian Society of Clinical Immunology and Allergy, 2013, AUSTR SOC CLIN IMM A
  • [2] Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach?
    Caminati, Marco
    Dama, Annarita
    Schiappoli, Michele
    Senna, Gianenrico
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (10) : 937 - 947
  • [3] Walnut allergens: molecular characterization, detection and clinical relevance
    Costa, J.
    Carrapatoso, I.
    Oliveira, M. B. P. P.
    Mafra, I.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2014, 44 (03) : 319 - 341
  • [4] Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet
    de Groot, Hans
    Bijl, Annemarie
    [J]. ALLERGY, 2009, 64 (06) : 963 - 964
  • [5] Anaphylaxis to multiple pollen allergen sublingual immunotherapy
    Eifan, A. O.
    Keles, S.
    Bahceciler, N. N.
    Barlan, I. B.
    [J]. ALLERGY, 2007, 62 (05) : 567 - 568
  • [6] Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents
    Halken, Susanne
    Agertoft, Lone
    Seidenberg, Juergen
    Bauer, Carl-Peter
    Payot, Francois
    Flora Martin-Munoz, Maria
    Bartkowiak-Emeryk, Malgorzata
    Vereda, Andrea
    Jean-Alphonse, Stephanie
    Melac, Michel
    Le Gall, Martine
    Wahn, Ulrich
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2010, 21 (06) : 970 - 976
  • [7] Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis
    Malling, H-J.
    Montagut, A.
    Melac, M.
    Patriarca, G.
    Panzner, P.
    Seberova, E.
    Didier, A.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (03) : 387 - 393
  • [8] Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen Induced Rhinoconjunctivitis
    Reich, Kristian
    Gessner, Christian
    Kroker, Axel
    Schwab, Jan Alexander
    Pohl, Wolfgang
    Villesen, Hanne
    Wuestenberg, Eike
    Emminger, Waltraud
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (07) : 828 - 840
  • [9] Safety and Tolerability of an Intra-seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-interventional Observational Study Investigating the Feasibility During Routine Administration
    Schwab, Jan-Alexander
    Wolf, Hendrik
    Schnitker, Joerg
    Wuestenberg, Eike
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 719 - 726
  • [10] Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis
    Wahn, Ulrich
    Tabar, Ana
    Kuna, Piotr
    Halken, Susanne
    Montagut, Armelle
    de Beaumont, Olivier
    Le Gall, Martine
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 160 - 166
1